Early viral suppression improves neurocognitive outcomes in HIV-infected children
- PMID: 25686678
- PMCID: PMC4332557
- DOI: 10.1097/QAD.0000000000000528
Early viral suppression improves neurocognitive outcomes in HIV-infected children
Abstract
Objective: To estimate the association of age of viral suppression and central nervous system penetration effectiveness (CPE) score with neurocognitive functioning among school-age children with perinatally acquired HIV infection (PHIV+).
Design: We analyzed data from two US-based multisite prospective cohort studies.
Methods: Multivariable general linear regression models were used to evaluate associations of age at viral suppression and CPE scores (of initial antiretroviral therapy regimen and weighted average) with the Wechsler Intelligence Scale for Children, Third or Fourth Edition neurocognitive assessments [Full-Scale Intelligence Quotient (FSIQ); Performance IQ/Perceptual Reasoning Index (PIQ/PRI); and Verbal IQ/Verbal Comprehension Index (VIQ/VCI)], adjusted for demographic and clinical covariates. Sensitivity analyses were stratified by birth cohort (before versus after 1996).
Results: A total of 396 PHIV+ children were included. Estimated differences in mean FSIQ (comparing virally suppressed versus unsuppressed children) by each age cutoff were 3.7, 2.2, 3.2, 4.4, and 3.9 points at ages 1, 2, 3, 4, and 5, respectively. For PIQ/PRI, estimated mean differences were 3.7, 2.4, 2.2, 4.6, and 4.5 at ages 1 through 5, respectively. In both cases, these differences were significant only at the age 4 and 5 thresholds. After stratifying by birth cohort, the association between age at suppression and cognitive function persisted only among those born after 1996. Age at viral suppression was not associated with VIQ/VCI; CPE score was not associated with FSIQ, verbal comprehension, or perceptual reasoning indices.
Conclusion: Virologic suppression during infancy or early childhood is associated with improved neurocognitive outcomes in school-aged PHIV+ children. In contrast, CPE scores showed no association with neurocognitive outcomes.
Figures


References
-
- Tamula MA, Wolters PL, Walsek C, Zeichner S, Civitello L. Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics. 2003;112:679–684. - PubMed
-
- Koekkoek S, de Sonneville LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profile in HIV-infected school-age children. Eur J Paediatr Neurol. 2008;12:290–297. - PubMed
-
- Paramesparan Y, Garvey LJ, Ashby J, Foster CJ, Fidler S, Winston A. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. J Acquir Immune Defic Syndr. 2010;55:134–136. - PubMed
-
- Crowell CS, Malee KM, Yogev R, Muller WJ. Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy. Rev Med Virol. 2014 - PubMed
-
- Zink WE, Zheng J, Persidsky Y, Poluektova L, Gendelman HE. The neuropathogenesis of HIV-1 infection. FEMS Immunol Med Microbiol. 1999;26:233–241. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 HD052104/HD/NICHD NIH HHS/United States
- N01 HD033345/HD/NICHD NIH HHS/United States
- U01 AI068632/AI/NIAID NIH HHS/United States
- UM1 AI068632/AI/NIAID NIH HHS/United States
- N01-3-3345/PHS HHS/United States
- HHSN267200800001C/HD/NICHD NIH HHS/United States
- P30 AI045008/AI/NIAID NIH HHS/United States
- U01 AI068616/AI/NIAID NIH HHS/United States
- U01 AI041110/AI/NIAID NIH HHS/United States
- UM1 AI068616/AI/NIAID NIH HHS/United States
- U01 HD052102/HD/NICHD NIH HHS/United States
- HD052104/HD/NICHD NIH HHS/United States
- U01 AI41110/AI/NIAID NIH HHS/United States
- HHSN267200800001C/DK/NIDDK NIH HHS/United States
- HD052102/HD/NICHD NIH HHS/United States
- U01AI068632/AI/NIAID NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous